DCPH Insider Trading Activity and SEC Form 4 Filings
DCPH insider trading summary
No open-market insider purchases or sales of Deciphera Pharmaceuticals, Inc. (DCPH) have been reported on SEC Form 4 in the past 12 months.
Latest DCPH insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 16, 2024 | Daniel C. Martin | Chief Commercial Officer | Sell | $35K (2,267 @ $15.62) |
| Feb 16, 2024 | Thomas Patrick Kelly | Chief Financial Officer | Sell | $47K (3,010 @ $15.62) |
| Feb 16, 2024 | Jama Pitman | SVP, Chief Development Officer | Sell | $35K (2,267 @ $15.62) |
| Feb 16, 2024 | Matthew L Sherman | EVP & Chief Medical Officer | Sell | $41K (2,615 @ $15.62) |
| Jan 16, 2024 | Matthew L Sherman | EVP & Chief Medical Officer | Sell | $35K (2,435 @ $14.47) |
| Jan 16, 2024 | Jama Pitman | SVP, Chief Development Officer | Sell | $23K (1,624 @ $14.47) |
| Jan 16, 2024 | Daniel C. Martin | Chief Commercial Officer | Sell | $23K (1,624 @ $14.47) |
| Jan 16, 2024 | Thomas Patrick Kelly | Chief Financial Officer | Sell | $35K (2,435 @ $14.47) |
| Dec 13, 2023 | Matthew L Sherman | EVP & Chief Medical Officer | Sell | $43K (2,792 @ $15.37) |
| Dec 13, 2023 | Thomas Patrick Kelly | Chief Financial Officer | Sell | $43K (2,792 @ $15.37) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.